Komori
Kaken Pharmaceutical (4521) · FactWorsenedLatest Financial results presentation (2026-11-09): "Softened"

Decline in Cash Flow from Operating Activities

First written in FY2019-Q2. 6 of 14 entries say "Worsened", first in FY2021-Q2. Latest entry: 2026-11-09.

14entries
9years
2from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorse2018: 12019: 220192020: 120202021: 220212022: 220222023: 120232024: 120242025: 120252026: 32026
Same theme, other companies

Kaken Pharmaceutical moved to the "Worse" side of this theme in 2020.

The whole theme swung hardest in 2018: 2 of 10 companies on the "Worse" side.

0 other companies' latest entry also says "Softened".

Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
  1. 2026-11-09SoftenedFinancial results presentation

    「営業活動によるキャッシュ・フロー △ 8,064 △ 11,079 14,192 22,256」

    営業活動によるキャッシュ・フローは前年同期の支出から14,192百万円の収入へ転じ、減少傾向が弱まった。
  2. FY2026WorsenedAnnual report

    「Cash flow from operating activities for the current consolidated fiscal year amounted to an outflow of ¥11,079 million, compared with an inflow of ¥29,780 million in the previous year. This was mainly due to an increase in income tax payments.」

    Cash flow from operating activities shifted from an inflow of ¥29,780 million in the previous fiscal year to an outflow of ¥11,079 million.
  3. 2026-05-13WorsenedResults

    「2026年3月期 △11,079 315 △8,841 50,705 2025年3月期 29,780 △19,650 △5,369 70,085」

    営業活動によるキャッシュ・フローは、2025年3月期の29,780百万円の収入から2026年3月期は11,079百万円の支出へ転じた。
  4. FY2026-H1WorsenedAnnual report

    「Cash flow from operating activities for the current interim consolidated accounting period amounted to an outflow of ¥8,064 million, a decrease of ¥31,997 million in cash inflows from the previous interim consolidated accounting period. This was mainly due to a decrease in interim profit before income taxes.」

    Cash flow from operating activities shifted from an inflow of ¥23,932 million in the previous interim period to an outflow of ¥8,064 million.
  5. FY2025-H1SoftenedAnnual report

    「Cash flow from operating activities for the current interim consolidated accounting period amounted to ¥23,932 million, an increase of ¥24,177 million in cash inflows from the previous interim consolidated accounting period. This was mainly due to interim profit before income taxes.」

    Cash flow from operating activities shifted from an outflow of ¥245 million in the previous interim consolidated accounting period to an inflow of ¥23,932 million, representing a significant improvement.
  6. FY2024-Q2WorsenedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to an outflow of ¥245 million, a decrease of ¥6,672 million in cash inflows from the same quarter of the previous year. This was mainly due to an increase in trade receivables.」

    Cash flow from operating activities shifted from an inflow in the previous year to an outflow of ¥245 million, with the increase in trade receivables cited as the primary factor.
  7. FY2023-Q2SoftenedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to ¥6,427 million, an increase of ¥993 million in cash inflows from the same quarter of the previous year. This was mainly due to an increase in trade payables.」

    Cash flow from operating activities increased by ¥993 million year on year to ¥6,427 million, improving from the downward trend that had continued from the previous fiscal year.
  8. FY2022RestatedAnnual report

    「Cash flow from operating activities for the current consolidated fiscal year amounted to ¥13,336 million, a decrease of ¥1,043 million in cash inflows from the previous consolidated fiscal year. This was mainly due to a decrease in profit before income taxes.」

    Cash flow from operating activities declined by ¥1,043 million year on year to ¥13,336 million, confirming a downward trend for the fiscal year as well.
  9. FY2022-Q2RestatedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to ¥5,434 million, a decrease of ¥1,257 million in cash inflows from the same quarter of the previous year. This was mainly due to an increase in trade receivables.」

    Cash flow from operating activities declined by ¥1,257 million year on year to ¥5,434 million, confirming that the downward trend continued into the cumulative second quarter of the current fiscal year.
  10. FY2021WorsenedAnnual report

    「Cash flow from operating activities for the current consolidated fiscal year amounted to ¥14,380 million, a decrease of ¥13,088 million in cash inflows from the previous consolidated fiscal year. This was mainly due to a decrease in profit before income taxes.」

    Cash flow from operating activities declined by ¥13,088 million year on year to ¥14,380 million, representing a larger annual decline than in the previous fiscal year.
  11. FY2021-Q2WorsenedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to ¥6,691 million, a decrease of ¥8,965 million in cash inflows from the same quarter of the previous year. This was mainly due to a decrease in changes in trade receivables.」

    Although cash flow from operating activities increased year on year in the cumulative second quarter of the previous fiscal year, it declined by ¥8,965 million in the cumulative second quarter of the current fiscal year.
  12. FY2020-Q2SoftenedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to ¥15,657 million, an increase of ¥8,617 million in cash inflows from the same quarter of the previous year. This was mainly due to a decrease in trade receivables.」

    Unlike the decline in cash flow from operating activities that continued through the previous fiscal year, cash flow increased by ¥8,617 million year on year to ¥15,657 million in the cumulative second quarter of the current fiscal year.
  13. FY2019RestatedAnnual report

    「Cash flow from operating activities for the current consolidated fiscal year amounted to ¥21,129 million, a decrease of ¥573 million in cash inflows from the previous consolidated fiscal year. This was mainly due to a decrease in profit before income taxes.」

    Cash flow from operating activities declined by ¥573 million year on year to ¥21,129 million, confirming a downward trend for the fiscal year as well.
  14. FY2019-Q2First statedAnnual report

    「Cash flow from operating activities for the cumulative second quarter of the current fiscal year amounted to ¥7,040 million, a decrease of ¥4,046 million in cash inflows from the same quarter of the previous year. This was mainly due to a decrease in trade payables.」

    Cash flow from operating activities declined by ¥4,046 million year on year to ¥7,040 million, with the decrease in trade payables cited as the primary factor.
Moved together

"Impact of drug price revisions and lower income from overseas licensees" moved the same way as this thread, in the same document, in 8 of its 14 moves.

876433★123456
  1. ★This thread
  2. 1Impact of drug price revisions and lower income from overseas licensees8×
  3. 2Recording of overseas revenue7×
  4. 3Declines in operating profit and net profit6×
  5. 4Jublia sales growth4×
  6. 5Risk of lower sales due to competition from other companies and generic drugs3×
  7. 6Decline in agricultural chemicals sales3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Kaken Pharmaceutical's next results are scheduled for 2026-11-09. Read the earnings preview It last moved in the Financial results presentation of 2026-11-09: "Softened".
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.